<DOC>
	<DOCNO>NCT00984945</DOCNO>
	<brief_summary>The primary objective ass safety tolerability two consecutive dos plant-based H5 VLP , ( H5N1 ) pandemic influenza vaccine combine Alhydrogel® , give 21 day apart , three dose level : 5µg , 10µg 20µg. , compare placebo , combine Alhydrogel® .</brief_summary>
	<brief_title>Safety Study Plant-based H5 Virus-Like Particles ( VLP ) Vaccine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>RNA Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female adult , 18 60 year age Healthy judge Principal Investigator ( PI ) determine medical history , physical examination , vital sign , screen laboratory medical history conduct 30 day prior study vaccine administration BMI ≥18 ≤29 Comprehension study requirement , express availability require study period ability attend schedule visit Accessible telephone consistent basis In opinion Investigator , competence willingness provide write , informed consent participation reading inform consent form . The subject must adequate opportunity discus study Investigator qualify designee If female capable childbearing , negative urine pregnancy test result study entry agree employ adequate birth control measure duration study Presence significant acute chronic , uncontrolled medical neuropsychiatric illness . `` Uncontrolled '' define : 1 . Requiring new medical surgical treatment within one month prior study vaccine administration 2 . Requiring change medication dosage one month prior test article administration due uncontrolled symptom drug toxicity ( elective dosage adjustment stable subject acceptable ) , 3 . Hospitalization event fulfil definition serious adverse event within one month prior test article administration Any medical neuropsychiatric condition , Investigator 's opinion , would render subject incompetent provide inform consent unable provide valid safety observation report Any confirm suspected immunosuppressive condition immunodeficiency include history human immunodeficiency virus ( HIV ) infection presence lymphoproliferative disease Presence febrile illness , oral temperature &gt; 38.0 C within 24 hour test article administration . Such subject may reevaluate enrolment resolution illness History autoimmune disease Administration vaccine ( include influenza vaccine ) within 30 day period prior study enrolment , plan administration within period first vaccination blood sample Day 42 within 30 day prior blood sample Day 228 . Immunization emergency basis tetanus diphtheria toxoid adsorb adult use ( Td ) allow provide vaccine administer within two week prior test article administration . Receipt emergency immunization ( e.g . rabies ) result casebycase review continue participation . Use investigational nonregistered product within 90 day prior study enrolment plan use study period . Subjects may participate drug study participate study Treatment systemic glucocorticoid dose exceed ≥ 10 mg prednisone per day , equivalent 7 consecutive day 10 day total , within one month first test article administration , cytotoxic immunosuppressant drug immune globulin preparation within three month vaccination . Nasal inhale glucocorticoid allow Any significant disorder coagulation treatment coumadin derivative heparin . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinically apparent bleeding tendency eligible History previous H5N1 vaccination History allergy constituent H5 VLP ( H5N1 ) study vaccine , Alhydrogel® ( aluminium hydroxide ) , phosphate buffer . History severe allergic reaction anaphylaxis History tobacco allergy Have receive blood transfusion immunoglobulin within 90 day study entry If female , childbearing potential , consistently use effective birth control 28 day prior study entry . An example highly effective birth control oral contraceptive , hormone implant , abstinence ( confirmed Investigator ) , male condom plus spermicide . All female subject , regardless birth control history must provide urine sample pregnancy screen . Effective birth control must use duration study . The subject must plan become pregnant study period . Females postmenopausal ( spot ) least two ( 2 ) year require urine pregnancy test . Among female subject , either know pregnancy urine betahuman chorionic gonadotropin ( ßhCG ) test result consistent pregnancy prior test article administration Day 0 Female subject lactate Vital sign abnormality : systolic blood pressure ≥150 mmHg , diastolic blood pressure ≥90 mmHg , rest pulse rate &lt; 40 bpm &gt; 100 bpm Cancer treatment cancer within 3 year test article administration . Persons history cancer diseasefree without treatment 3 year eligible . Persons treat uncomplicated basal cell carcinoma skin eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>pandemic vaccine</keyword>
	<keyword>influenza</keyword>
	<keyword>H5N1</keyword>
	<keyword>Virus Like Particle ( VLP )</keyword>
</DOC>